Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease | Latest News RSS feed

Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease - Latest News


Merck (MRK) Reports Phase 3 KEYNOTE-181 Trial Investigating KEYTRUDA Met a Primary Endpoint of OS in Patients Whose Tumors Express PD-L1

The primary endpoint of OS was also evaluated in patients with squamous cell histology and in the entire intention-to-treat ... should have disease progression on FDA-approved therapy for these aberra... read more

Prostate RT Ups Overall Survival in Metastatic Disease

Patients ... the treatment groups and dominated by side effects of ADT. "We've proven the principle in prostate cancer, that treating the primary tumor can improve survival in men with metastatic dise... read more

Herbst Highlights Next Steps With Immunotherapy in Lung Cancer

Because only a small percentage of this patient ... metastatic disease, it was uniformly fatal. Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Tr... read more

Looking for another news?


5 Companies Tackling Breast Cancer In The Second Half Of 2018

Talazoparib, observed in 431 patients with inherited BRCA1/2 mutations, met its primary ... the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women with disease ... read more


Monteris Medical Announces the Publication of Positive Clinical Data for Its NeuroBlate® Laser System for Patients with Brain Metastasis

Nov. 12, 2018 /PRNewswire/ -- Monteris Medical ... "SRS is an effective first-line treatment for patients with metastatic brain cancer. However, for patients with recurrent disease that may not be app... read more

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

About LORBRENA® (lorlatinib) LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progress... read more

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?

This phase III trial compared Nivolumab (Nivo) plus ipilimumab (Ipi) versus Sunitinib in International Metastatic ... later in the disease process. Is it possible that we are using our best treatment ... read more

ReDOS Trial: Optimizing Regorafenib Dosing in metastatic Colorectal Cancer

When we [looked] at the primary ... Patients are having better survival outcomes because of that. Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing ... read more

A State of Flux for Kidney Cancer

The most common treatment for early-stage ... nephrectomy improves survival in patients with metastatic disease, even though it doesn’t remove all disease. Hartstein learned that he had small lung nod... read more

Sequential, Initial Combo Tx for Colon Ca on Par in XELAVIRI Trial

The study's primary endpoint was the noninferiority, by the measure of TFS of initial treatment ... metastatic colon cancer. While there may be many reasons to choose a 'chemo-light' strategy, such as ... read more

ESMO 2018: Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden

Yet, the authors hypothesized that treatment to the primary ... should be standard of care in men with low metastatic burden in addition to systemic therapy. He also feels that this may be translatabl... read more

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2018 Results - Earnings Call Transcript

Calithera Biosciences, Inc. (NASDAQ:CALA) Q3 2018 ... treated with CB-839 plus cabozantinib and were evaluable for response. Patients enrolled in the trial have advanced a metastatic disease ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us